Welcome to LookChem.com Sign In|Join Free
  • or
Edoxaban hydrochloride, also known as Lixiana, is a direct inhibitor of Factor Xa (FXa) that was approved by the Minister of Health, Labor, and Welfare in Japan in April 2011. It is primarily used for the prevention of venous thromboembolism (VTE) after major orthopedic surgery. Edoxaban exhibits a high degree of selectivity for FXa, with a Ki value of 0.56 nM, and is a weak inhibitor of thrombin with a Ki value of 6000 nM. It also demonstrates selectivity over other serine proteases in the coagulation cascade and over trypsin and chymotrypsin. The synthesis of this class of FXa inhibitors starts with the assembly of the diaminocyclohexane scaffold, followed by the coupling of the P1 and P4 groups.

480448-29-1

Post Buying Request

480448-29-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

480448-29-1 Usage

Uses

Used in Pharmaceutical Industry:
Edoxaban hydrochloride is used as an anticoagulant for the prevention of venous thromboembolism (VTE) after major orthopedic surgery. It functions by directly inhibiting Factor Xa (FXa), a key enzyme in the coagulation cascade, with high selectivity and potency. This selective inhibition helps to reduce the risk of blood clot formation without significantly affecting other serine proteases or trypsin and chymotrypsin, thus minimizing the risk of bleeding complications.
Used in Research and Development:
Edoxaban hydrochloride is also utilized in the research and development of novel anticoagulant therapies. Its high selectivity for FXa makes it a valuable compound for studying the role of FXa in various coagulation-related disorders and for developing new drugs with improved safety and efficacy profiles.

Originator

Daiichi Pharmaceutical (Japan)

Check Digit Verification of cas no

The CAS Registry Mumber 480448-29-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,8,0,4,4 and 8 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 480448-29:
(8*4)+(7*8)+(6*0)+(5*4)+(4*4)+(3*8)+(2*2)+(1*9)=161
161 % 10 = 1
So 480448-29-1 is a valid CAS Registry Number.

480448-29-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name N-[(1S,2R,4S)-4-carbamoyl-2-[(7-methyl-4,5,6,8-tetrahydropyrido[4,3-e][1,3]thiazine-2-carbonyl)amino]cyclohexyl]-N'-(5-chloropyridin-2-yl)oxamide,hydrochloride

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:480448-29-1 SDS

480448-29-1Upstream product

480448-29-1Downstream Products

480448-29-1Relevant academic research and scientific papers

SUSTAINED-RELEASE SOLID PREPARATION FOR ORAL USE

-

, (2013/02/28)

It is intended to avoid dose dumping of a drug and improve the dissolution properties of the drug in the lower gastrointestinal tract, and thereby provide a sustained-release matrix preparation for oral administration that reliably exhibits its main pharmacological effect when orally administered once or twice a day. The present invention provides a sustained-release preparation obtained by mixing of (A) a pharmacologically active drug, (B) hydroxypropyl methylcellulose acetate succinate having a median size (D50) of 40 μm or smaller, (C) a cellulose derivative, and (D) a saccharide or a nonionic water-soluble polymer followed by molding.

SUSTAINED-RELEASE SOLID PREPARATION FOR ORAL USE

-

, (2013/02/28)

It is intended to avoid dose dumping of a drug and improve the dissolution properties of a drug in the lower gastrointestinal tract, and thereby provide a sustained-release solid preparation for oral administration that reliably exhibits its main pharmacological effect when orally administered once or twice a day. The present invention provides a sustained-release solid preparation containing (A) a pharmacologically active drug, (B) carboxyvinyl polymer, (C) povidone, and (D) carmellose sodium, xanthan gum, or sodium carboxymethyl starch.

SUSTAINED-RELEASE SOLID PREPARATION FOR ORAL USE

-

, (2013/02/28)

It is intended to avoid dose dumping of a drug and improve the dissolution properties of the drug in the lower gastrointestinal tract, and thereby provide a sustained-release pellet preparation for oral administration that reliably exhibits its main pharmacological effect when orally administered once or twice a day. The present invention provides a sustained-release preparation obtained by mixing of (A) a pharmacologically active drug, (B) hydroxypropyl methylcellulose acetate succinate, (C) a plasticizer, and (D) polyethylene glycol followed by extrusion granulation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 480448-29-1